A business in context

ATRA research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-09-07 · 8010 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 4 · Ownership change

    Report date 2026-09-04 · 0000905148-26-004085

  2. 4 · Ownership change

    Report date 2026-08-17 · 0000905148-26-003960

  3. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001193125-26-346885

  4. 8-K · Current report

    Report date 2026-08-12 · 0001193125-26-346857 · Items 2.02

  5. 4 · Ownership change

    Report date 2026-07-22 · 0001104659-26-086733

  6. 8-K · Current report

    Report date 2026-06-22 · 0001193125-26-285498 · Items 5.02

  7. 4 · Ownership change

    Report date 2026-06-11 · 0000905148-26-002951

  8. 8-K · Current report

    Report date 2026-06-09 · 0001213900-26-068264 · Items 5.02,5.07

  9. 4 · Ownership change

    Report date 2026-06-09 · 0000905148-26-002921

  10. 4 · Ownership change

    Report date 2026-06-09 · 0000905148-26-002920

  11. 4 · Ownership change

    Report date 2026-06-09 · 0000905148-26-002919

  12. 4 · Ownership change

    Report date 2026-05-18 · 0000905148-26-002571

  13. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001193125-26-219482

  14. 8-K · Current report

    Report date 2026-05-12 · 0001193125-26-219420 · Items 9.01

  15. 8-K · Current report

    Report date 2026-05-07 · 0001193125-26-210413 · Items 8.01

  16. 8-K · Current report

    Report date 2026-04-30 · 0001193125-26-201397 · Items 3.01

  17. DEF 14A · Proxy statement

    Report date 2026-04-24 · 0001193125-26-177285

  18. 10-K · Annual report

    Report date 2025-12-31 · 0001193125-26-108361

  19. 8-K · Current report

    Report date 2026-03-16 · 0001193125-26-108344 · Items 2.02,9.01

  20. 8-K · Current report

    Report date 2026-03-12 · 0001193125-26-103127 · Items 8.01,9.01

  21. 8-K · Current report

    Report date 2026-03-03 · 0001193125-26-086793 · Items 8.01,9.01

  22. 8-K · Current report

    Report date 2026-02-20 · 0001193125-26-062534 · Items 1.01,3.02,8.01,9.01

  23. 8-K · Current report

    Report date 2026-01-12 · 0001193125-26-010342 · Items 2.02,8.01,9.01

  24. 8-K · Current report

    Report date 2025-12-30 · 0001193125-26-000907 · Items 1.01,9.01

  25. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001193125-25-276219

  26. 8-K · Current report

    Report date 2025-11-12 · 0001193125-25-276209 · Items 2.02,9.01

  27. 8-K · Current report

    Report date 2025-10-06 · 0001193125-25-232117 · Items 2.05

  28. 8-K · Current report

    Report date 2025-09-02 · 0000950170-25-112898 · Items 5.02

  29. 10-Q · Quarterly report

    Report date 2025-06-30 · 0000950170-25-106550

  30. 8-K · Current report

    Report date 2025-08-11 · 0000950170-25-106533 · Items 2.02,9.01

  31. 8-K · Current report

    Report date 2025-07-14 · 0001193125-25-158719 · Items 2.02,8.01,9.01

  32. 8-K · Current report

    Report date 2025-06-10 · 0001193125-25-139150 · Items 5.07

  33. 8-K · Current report

    Report date 2025-05-14 · 0001193125-25-121824 · Items 8.01,9.01

  34. 8-K · Current report

    Report date 2025-05-14 · 0001193125-25-120345 · Items 2.02,5.02,9.01

  35. 10-Q · Quarterly report

    Report date 2025-03-31 · 0000950170-25-072040

  36. 8-K · Current report

    Report date 2025-05-12 · 0000950170-25-069198 · Items 2.05

  37. 8-K · Current report

    Report date 2025-05-05 · 0001193125-25-113811 · Items 8.01,9.01

  38. DEF 14A · Proxy statement

    Report date 2025-06-10 · 0000950170-25-059322

  39. 8-K · Current report

    Report date 2025-03-31 · 0000950170-25-051121 · Items 1.01

  40. 8-K · Current report

    Report date 2025-03-25 · 0001193125-25-068789 · Items 5.02

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-09-07 · 2026 Q2: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 1 transaction rows1PSale: 3 transaction rows3SGrant / award: 4 transaction rows4AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

8 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-06-11
2026-06-15
Cherry Brian NA · Grant / award
Acquired
Common Stock24000.00.0
2026-06-09
2026-06-11
HEIDEN WILLIAM KA · Grant / award
Acquired
Common Stock12000.00.0
2026-06-09
2026-06-11
Fust Matthew KA · Grant / award
Acquired
Common Stock12000.00.0
2026-06-09
2026-06-11
Ciongoli Gregory AustinA · Grant / award
Acquired
Common Stock12000.00.0
2026-05-18
2026-05-20
Nguyen AnhCoS · Sale
Disposed
Common Stock5241.09.13
2026-05-18
2026-05-20
Grant-Huerta YaninaS · Sale
Disposed
Common Stock2414.09.13
2026-05-07
2026-05-11
Huang James; Panacea Innovation LtdS · Sale
Disposed
Common Stock313446.010.1
2026-05-07
2026-05-11
EcoR1 Capital, LLCP · Purchase
Acquired
Common Stock507407.09.35

Identity & relationships

Wikidata structured data · retrieved 2026-09-07 · 1611 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001604464Atara Biotherapeutics, Inc.

No parent relationship is available in this import; this is not proof of independence.

Legal Entity Identifier
549300WBXUXZRE03MS38
GLEIF legal name
Atara Biotherapeutics, Inc.
Entity / LEI registration status
ACTIVE / LAPSED
Reference data updated
2023-08-04T17:29:47Z

direct-parent: no parent LEI supplied

ultimate-parent: no parent LEI supplied

GLEIF legal entity reference data · retrieved 2026-09-07 · 1177 checked identities; 0 unavailable records

Search names and former names

View Wikidata identity and references ↗

  • Atara Biotherapeutics · alias · wikidata
  • Atara Bio · alias · wikidata
  • NASDAQ:ATRA · alias · wikidata
Explore headquarters map ↗

Revenue in constant purchasing power

USD revenue expressed in 2026-07 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2024-12-31$128.94M$137.25M
2023-12-31$8.57M$9.39M
2022-12-31$63.57M$72.52M

Bureau of Labor Statistics · retrieved 2026-09-07 · 9 selected series; gaps remain missing

Explore the CPI history ↗